Mylan Completes Acquisition of Generics Business of Merck KGaA

Pittsburgh (USA) 3 October (PROTEXT/PRNewswire) - Mylan (NYSE: MYL)yesterday announced that it has completed its acquisition of Merck KGaA'sgenerics business ("Merck Generics") to become one of the largest qualitygenerics and specialty pharmaceuticals companies in the world. Mylan andMerck KGaA initially announced the signing of a definitive agreement underwhich Mylan would acquire Merck Generics for EUR 4.9 billion (US$6.8billion) in an all-cash transaction on May 12, 2007.

Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer said:"The new Mylan now has all of the critical attributes we need to ensurefuture success and deliver powerful growth. We have enhanced scale andstability, a truly global reach, vertical and horizontal integration, andbreadth and depth in our management team. Most importantly, we have acommon purpose and dedication to executing on our strategy and deliveringsuperior shareholder returns."

The new Mylan is the third largest generic company worldwide, employs morethan 11,000 people and has a global presence in more than 90 countries.

Mylan's broad product offering now includes more than 570 products and theworld's second largest portfolio of active pharmaceutical ingredients(APIs) with 126 U.S. drug master files (DMFs). Mylan has a powerful globalpipeline with more than 255 applications or dossiers pending regulatoryapproval. The new Mylan will benefit from substantial operationalefficiencies and economies of scale from increased sales volumes and itsvertically and horizontally integrated platform. Dey, Mylan's specialtypharmaceuticals business, brings additional exciting and diversifiedopportunities through its existing strengths in the respiratory arena.

Mr. Coury continued: "The scale of the new Mylan is evident in every areaof our business: we have scale in our geographic reach, scale in R&D, scalein manufacturing, scale in API, scale in our combined product portfolio,and scale in our global commercial footprint. We will leverage this scaleto drive operational efficiencies and extract synergies from our combinedcompany, while attracting exciting new opportunities. We have also createdan extremely well-balanced and diversified company, with significantlyreduced risks related to any one particular market or product. Importantly,we will also ensure that we retain the qualities that customers around theworld have come to expect from both Mylan and Merck Generics.

"The Merck Generics business is even stronger than we expected and, throughthe integration planning, we have confirmed that we truly share a commonculture and values centered on quality, integrity, reliability and service.I am thrilled to welcome Merck Generics nearly 5,000 employees to the newand expanded Mylan family. After months of careful preparation, we have hitthe ground running with the integration of our businesses and I amdelighted that we will be operating as a single, integrated company fromday one."

Mylan also announced today that the company will change its name from MylanLaboratories Inc. to Mylan Inc. to better reflect the broader scope of itsbusiness. The Company also confirmed that it has changed its financial yearto begin reporting on a calendar year basis.

Investor Day on October 3

Mylan will provide more details on its go-forward strategy and itsfinancial outlook during its Investor Day in New York, New York, on October3, 2007. The agenda will include presentations delivered by each of Mylan'sglobal regional heads and several members of Mylan's senior managementteam. The presentations will be available live via webcast beginning at8:30 a.m.ET.

To access the live webcast, go to Mylan's Web site at www.mylan.com andclick on the webcast icon at least 15 minutes before the event is scheduledto begin to register and download or install any necessary audio software.A replay of the webcast will be available on www.mylan.com until November2, 2007.

About Mylan

Mylan Inc. is one of the world's leading quality generic and specialtypharmaceutical companies. The Company offers one of the industry's broadestand highest quality product portfolios, a robust product pipeline and aglobal commercial footprint through operations in more than 90 countries.

Through its controlling interest in Matrix Laboratories Limited, Mylan hasdirect access to one of the largest active pharmaceutical ingredient (API)manufacturers in the world. Dey L.P., Mylan's fully integrated specialtybusiness, provides the Company with innovative and diversifiedopportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, please, visit http://www.mylan.com.

Forward-Looking Statements

This press release contains statements that constitute "forward-lookingstatements", including with regard to Mylan's future success, theanticipated benefits of operational efficiencies and leverage, and expectedproduct and other opportunities. These statements are made pursuant to thesafe harbor provisions of the Private Securities Litigation Reform Act of1995. Because such statements inherently involve risks and uncertainties,actual future results may differ materially from those expressed or impliedby such forward-looking statements. Factors that could cause or contributeto such differences include, but are not limited to: challenges and costsrelating to integration of the two businesses; the effect of any changes incustomer and supplier relationships and customer purchasing patterns; theimpact and effects of legal or regulatory proceedings, actions or changes;general market perception of the transaction; the ability to attract andretain key personnel; changes in economic and financial conditions of theCompany's business; uncertainties and matters beyond the control ofmanagement; and the other risks detailed in the Form 10-Q for the quarterended June 30, 2007 and the other periodic reports filed by the Companywith the Securities and Exchange Commission. The Company undertakes noobligation to update these statements for revisions or changes after thedate of this release.

Web site: http://www.mylan.com

Source: Mylan Inc.

Contact: Kris King, Mylan Inc., tel.: +1-724-514-1800; Nina Devlin or CindyLeggett-Flynn, Brunswick Group, tel.: +1-212-333-3810, for Mylan Inc.

Subscribers please note that material bearing the label "PROTEXT" is notpart of CTK's news service and is not to be published under the "CTK"label. Protext is a commercial service providing distribution of pressreleases from clients, who are identified in the text of Protext reportsand who bear full responsibility for their contents.

PROTEXT